Dimed S.A. Distribuidora de Medicamentos

BOVESPA:PNVL3 Stock Report

Market Cap: R$1.3b

Dimed Distribuidora de Medicamentos Past Earnings Performance

Past criteria checks 2/6

Dimed Distribuidora de Medicamentos has been growing earnings at an average annual rate of 10.1%, while the Consumer Retailing industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 13.6% per year. Dimed Distribuidora de Medicamentos's return on equity is 7.8%, and it has net margins of 2%.

Key information

10.13%

Earnings growth rate

9.43%

EPS growth rate

Consumer Retailing Industry Growth9.24%
Revenue growth rate13.58%
Return on equity7.82%
Net Margin1.96%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

author-image

Digital Strategy And AI Investments Will Improve Efficiency In Pharma Retail

Mar 13 Panvel's digital strategy and investment in AI tools boost sales and improve margins through increased efficiencies and tech-savvy customer engagement.

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17
Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04
Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12
These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27
Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15
Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25
Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06
The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23
Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15
Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Revenue & Expenses Breakdown

How Dimed Distribuidora de Medicamentos makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BOVESPA:PNVL3 Revenue, expenses and earnings (BRL Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 254,975971,3870
31 Dec 244,9421061,3680
30 Sep 244,8181041,3400
30 Jun 244,712911,3060
31 Mar 244,6601081,2720
31 Dec 234,461931,2100
30 Sep 234,325881,1660
30 Jun 234,211831,1470
31 Mar 234,116841,1250
31 Dec 223,990861,0990
30 Sep 223,799851,0560
30 Jun 223,584839950
31 Mar 223,375809420
31 Dec 213,225799070
30 Sep 213,135798600
30 Jun 213,032798250
31 Mar 212,878627700
31 Dec 202,819567260
30 Sep 202,764567180
30 Jun 202,754627040
31 Mar 202,780786990
31 Dec 192,725776870
30 Sep 192,638806580
30 Jun 192,562796420
31 Mar 192,500766260
31 Dec 182,432756090
30 Sep 182,359656010
30 Jun 182,317595890
31 Mar 182,282595800
31 Dec 172,258605710
30 Sep 172,238605560
30 Jun 172,191595480
31 Mar 172,146575680
31 Dec 162,129535580
30 Sep 162,095535390
30 Jun 162,074505220
31 Mar 162,043504760
31 Dec 151,986454620
30 Sep 151,963444470
30 Jun 151,927434360
31 Mar 151,916484320
31 Dec 141,887494240
30 Sep 141,835504270
30 Jun 141,823584140

Quality Earnings: PNVL3 has high quality earnings.

Growing Profit Margin: PNVL3's current net profit margins (2%) are lower than last year (2.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PNVL3's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: PNVL3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PNVL3 had negative earnings growth (-10%) over the past year, making it difficult to compare to the Consumer Retailing industry average (16.3%).

Return on Equity

High ROE: PNVL3's Return on Equity (7.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 14:08
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dimed S.A. Distribuidora de Medicamentos is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários
Francisco NavarreteBradesco S.A. Corretora de Títulos e Valores Mobiliários
Frederico MendesBradesco S.A. Corretora de Títulos e Valores Mobiliários